Targeting epidermal growth factor receptor in lung cancer

Perspective from the Asia-Pacific region

H. Eugene Liu, Ken Hong Lim, Ming Jer Huang, Biing Shiun Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is frequently overexpressed in non-small cell lung cancer (NSCLC), and has been identified as a novel therapeutic target for lung cancer. The development of small molecule EGFR-tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib has resulted in paradigm shift in the treatment of advanced NSCLC. The impact of EGFR-TKI in the treatment of NSCLC is even greater in Asia-Pacific region because one of the greatest clinical benefits of EGFR-TKI has been seen in patients of East Asian ethnicity. The discovery of somatic mutations in EGFR-tyrosine kinase domain has so far answered some, but not all, of the questions regarding the clinical response to EGFR-TKI in NSCLC. In addition, other molecular profiles such as KRAS mutations have also been found to play an important role in EGFR targeted therapy. In this article, we review EGFR targeted therapy in NSCLC with the focus on perspective from the Asia-Pacific region.

Original languageEnglish
Pages (from-to)22-31
Number of pages10
JournalAsia-Pacific Journal of Clinical Oncology
Volume2
Issue number1
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Mutation
Receptor Protein-Tyrosine Kinases

Keywords

  • Epidermal growth factor receptor
  • Erlotinib
  • Gefitinib
  • Mutation
  • Non-small cell lung carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting epidermal growth factor receptor in lung cancer : Perspective from the Asia-Pacific region. / Liu, H. Eugene; Lim, Ken Hong; Huang, Ming Jer; Huang, Biing Shiun.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 2, No. 1, 03.2006, p. 22-31.

Research output: Contribution to journalArticle

@article{ba0a3a9e37164c0bb288665a23edbf2f,
title = "Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region",
abstract = "The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is frequently overexpressed in non-small cell lung cancer (NSCLC), and has been identified as a novel therapeutic target for lung cancer. The development of small molecule EGFR-tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib has resulted in paradigm shift in the treatment of advanced NSCLC. The impact of EGFR-TKI in the treatment of NSCLC is even greater in Asia-Pacific region because one of the greatest clinical benefits of EGFR-TKI has been seen in patients of East Asian ethnicity. The discovery of somatic mutations in EGFR-tyrosine kinase domain has so far answered some, but not all, of the questions regarding the clinical response to EGFR-TKI in NSCLC. In addition, other molecular profiles such as KRAS mutations have also been found to play an important role in EGFR targeted therapy. In this article, we review EGFR targeted therapy in NSCLC with the focus on perspective from the Asia-Pacific region.",
keywords = "Epidermal growth factor receptor, Erlotinib, Gefitinib, Mutation, Non-small cell lung carcinoma",
author = "Liu, {H. Eugene} and Lim, {Ken Hong} and Huang, {Ming Jer} and Huang, {Biing Shiun}",
year = "2006",
month = "3",
doi = "10.1111/j.1743-7563.2006.00043.x",
language = "English",
volume = "2",
pages = "22--31",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Targeting epidermal growth factor receptor in lung cancer

T2 - Perspective from the Asia-Pacific region

AU - Liu, H. Eugene

AU - Lim, Ken Hong

AU - Huang, Ming Jer

AU - Huang, Biing Shiun

PY - 2006/3

Y1 - 2006/3

N2 - The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is frequently overexpressed in non-small cell lung cancer (NSCLC), and has been identified as a novel therapeutic target for lung cancer. The development of small molecule EGFR-tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib has resulted in paradigm shift in the treatment of advanced NSCLC. The impact of EGFR-TKI in the treatment of NSCLC is even greater in Asia-Pacific region because one of the greatest clinical benefits of EGFR-TKI has been seen in patients of East Asian ethnicity. The discovery of somatic mutations in EGFR-tyrosine kinase domain has so far answered some, but not all, of the questions regarding the clinical response to EGFR-TKI in NSCLC. In addition, other molecular profiles such as KRAS mutations have also been found to play an important role in EGFR targeted therapy. In this article, we review EGFR targeted therapy in NSCLC with the focus on perspective from the Asia-Pacific region.

AB - The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is frequently overexpressed in non-small cell lung cancer (NSCLC), and has been identified as a novel therapeutic target for lung cancer. The development of small molecule EGFR-tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib has resulted in paradigm shift in the treatment of advanced NSCLC. The impact of EGFR-TKI in the treatment of NSCLC is even greater in Asia-Pacific region because one of the greatest clinical benefits of EGFR-TKI has been seen in patients of East Asian ethnicity. The discovery of somatic mutations in EGFR-tyrosine kinase domain has so far answered some, but not all, of the questions regarding the clinical response to EGFR-TKI in NSCLC. In addition, other molecular profiles such as KRAS mutations have also been found to play an important role in EGFR targeted therapy. In this article, we review EGFR targeted therapy in NSCLC with the focus on perspective from the Asia-Pacific region.

KW - Epidermal growth factor receptor

KW - Erlotinib

KW - Gefitinib

KW - Mutation

KW - Non-small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33644695038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644695038&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2006.00043.x

DO - 10.1111/j.1743-7563.2006.00043.x

M3 - Article

VL - 2

SP - 22

EP - 31

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 1

ER -